Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

divarasib (RG6330)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

KRAS G12C inhibitor

Related drugs:

KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	cetuximab + RG6330 Sensitive: C3 – Early Trials cetuximab + RG6330 Sensitive : C3	cetuximab + RG6330 Sensitive: C3 – Early Trials cetuximab + RG6330 Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	RG6330 + RLY-1971 Sensitive: D – Preclinical RG6330 + RLY-1971 Sensitive : D	RG6330 + RLY-1971 Sensitive: D – Preclinical RG6330 + RLY-1971 Sensitive : D
EGFR amplification	Esophageal Squamous Cell Carcinoma	EGFR amplification	Esophageal Squamous Cell Carcinoma	RG6330 Sensitive: D – Preclinical RG6330 Sensitive : D	RG6330 Sensitive: D – Preclinical RG6330 Sensitive : D